On December 07, 2015 Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis and serious endocrine-related diseases, including hormone-responsive breast cancer,reported that it will host a conference call and webcast on Thursday, December 10, 2015, at 8 PM EST to provide an update on new data being presented on the investigational drug RAD1901 at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, TX, December 8-12 (Press release, Radius, DEC 7, 2015, View Source [SID:1234508470]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

RAD1901 is an investigational oral, selective estrogen receptor degrader (SERD) being evaluated for the potential treatment of hormone-driven, or hormone-resistant, metastatic breast cancer. RAD1901 has demonstrated potent single-agent and combination efficacy in ER+ primary patient derived xenograft animal models, including those harboring ESR1 mutations. These preclinical results, together with ongoing clinical data from Phase I monotherapy dose escalation trials, strongly support the further investigation of RAD1901 in patients with ER+ and endocrine-resistant disease.

RAD1901 Poster Presentation Details:

Title: RAD1901, a Novel Oral, Selective Estrogen Receptor Degrader ("SERD") with Single Agent Efficacy in ER+ Primary Patient Derived ERS1 Mutant Xenograft Model
Abstract Number: P3-05-07
Session/Poster: Poster Session 3, Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Date and Time: Thursday, December 10, 2015, 5:00 PM – 7:00 PM CT (6:00 PM – 8:00 PM ET)
Location: Henry B. Gonzalez Convention Center, Halls A-B

Title: A Phase 1 Study of RAD1901, a Novel, Orally Available, Selective Estrogen Receptor Degrader, for the Treatment of ER Positive Advanced Breast Cancer
Abstract Number: OT2-01-10
Session/Poster: Ongoing Clinical Trials: Ongoing Trials — Endocrine Therapies
Date and Time: Thursday, December 10, 2015 5:00 PM – 7:00 PM CT (6:00 PM – 8:00 PM ET)
Location: Henry B. Gonzalez Convention Center, Halls A-B

Title: A Phase 1 Dose Escalation Study of RAD1901, an Oral Selective Estrogen Receptor Degrader, in Healthy Postmenopausal Women
Abstract Number: P6-13-02
Session/Poster: Poster Session 6, Treatment: New Drugs and Treatment Strategies
Date and Time: Saturday, December 12, 2015, 7:30 AM – 9:00 AM CT (8:30 AM – 10:00 AM ET)
Location: Henry B. Gonzalez Convention Center, Hall C

Conference Call and Webcast

Radius will host a conference call and live audio webcast at 8:00 PM ET (7:00 PM CT) on Thursday, December 10, 2015 to provide an update on the RAD1901 data being presented at SABCS.

Conference Call and Webcast Information:
Date: Thursday, December 10, 2015
Time: 8:00 PM ET (7:00 PM CT)
Domestic Dial-in Number: 1-877-705-6003
International Dial-in Number: 1-201-493-6725
Live webcast: View Source

Replay of the call information:
Domestic Dial-In Number: 1-877-870-5176
International Dial-in Number: 1-858-384-5517
Replay Pin Number 13626630